Therefore, the inhibitory effect of tau on BDNF [93] and TyrRS, which activates H3‐Ser‐ADP‐ribosylation [11], is consistent with our previous finding that H3‐Ser‐ADP‐ribosylation is decreased in AD brains [11], and patients treated with tamoxifen (that increases H3‐Ser‐ADPR [71]) are protected against AD [176, 177] and CVDs [178, 179]. The gene discussed is MAPT; the disease is Alzheimer disease.